HARBOUR BIOMED Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- HARBOUR BIOMED's estimated annual revenue is currently $10.9M per year.
- HARBOUR BIOMED received $85.0M in venture funding in August 2018.
- HARBOUR BIOMED's estimated revenue per employee is $144,667
- HARBOUR BIOMED's total funding is $135M.
- HARBOUR BIOMED has 75 Employees.
- HARBOUR BIOMED grew their employee count by 14% last year.
- HARBOUR BIOMED currently has 1 job openings.
|Timothy Miller||Associate Director of Business Development and Alliances|
|Michael Lee||Senior Director|
|Shuyi Tang||Associate Director|
|Atul Deshpande Ph.D.||Chief Strategy Officer & Head, US Operations|
|Xiaoxiang Chen||Chief Development Officer|
|Mai-Jing Liao||Chief Business Officer|
|George Liu||VP/Head of Early Development and Scientific Operation|
|Atul Deshpande||Chief Strategy Officer and Head of U.S. Operations|
|Frank Grosveld||Founding Chief Scientific Officer|
What Is HARBOUR BIOMED?
Harbour BioMed is a global biotechnology company discovering and developing innovative therapeutics for cancer with a focus on immuno-oncology. The company's discovery and development programs are centered around its two patented transgenic mouse platforms for human antibody discovery. The company is building its proprietary pipeline internally, through collaborations with co-development partners, and selective preclinical and clinical stage asset acquisitions. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary. Learn more about Harbour Biomed: www.harbourbiomed.com/keywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
HARBOUR BIOMED News
CAMBRIDGE, Mass. & SHANGHAI & ROTTERDAM, Netherlands--(BUSINESS WIRE)--Harbour BioMed announced the appointment of Atul
Members include: AffyImmune Therapeutics, Abcuro Inc., ArrowDots BioMedicals, Extend Biosciences, Harbour Biomed, Siamab Therapeutics,
SHANGHAI & ROTTERDAM, The Netherlands & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Harbour BioMed announced today that it has
HARBOUR BIOMED Funding
|2018-08-27||$85.0M||B||GIC Private Limited,||Article|
HARBOUR BIOMED Executive Hires
|2019-01-07||Atul Deshpande||Chief Strategy Officer and Head of U.S. Operations||Article|